Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scienture Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scienture Holdings's position in the market.
Scienture Holdings (NASDAQ: SCNX), a specialty pharma company focused on novel brand products, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company's management team will present their corporate strategy and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth plans, and investment opportunities.
Scienture (NASDAQ: SCNX) announced that the U.S. Patent and Trademark Office has issued a new patent (No. 12,156,869) for its product SCN-102, a Losartan Potassium Oral Suspension. This patent, along with the previously granted patent No. 11,890,273, covers stable liquid pharmaceutical compositions of Losartan and treatment methods. Both patents extend protection through 2041.
The company's SCN-102 product, currently under FDA review, aims to provide a ready-to-use oral liquid formulation of Losartan, one of the most widely prescribed molecules in its class. The patents demonstrate Scienture's development capabilities and commitment to addressing underserved patient needs.
Scienture Holdings (NASDAQ: SCNX) has secured two strategic financing arrangements: a private placement of 10% secured convertible debentures worth up to $12.22 million to be issued in three tranches to Arena Investors affiliates, and a $50 million equity line of credit (ELOC) agreement with Arena Business Solutions. The first tranche of approximately $3.33 million in debentures was completed on November 25, 2024. Dawson James Securities served as the sole placement agent. The ELOC allows Scienture to issue and sell up to $50 million in common stock over 36 months, though the company has no immediate plans to utilize it. Proceeds will support working capital and general corporate purposes.
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX", effective September 23, 2024. The company will continue to trade on the Nasdaq Stock Market. Scienture Holdings, Inc., through its wholly owned subsidiaries Scienture and Integra Pharma Solutions, , is a comprehensive pharmaceutical product company focused on providing novel specialty products to meet unmet market needs.
The company's products are in development across various therapeutic areas and indications, catering to different market segments and channels. The executive team and board of directors consist of experienced industry veterans, including Suren Ajjarapu as CEO and Chairman, Prashant Patel as President, Interim CFO and COO, and other accomplished members.
FAQ
What is the current stock price of Scienture Holdings (SCNX)?
What is the market cap of Scienture Holdings (SCNX)?
